behaelterbau

Coating tanks

Process tanks for spraying and coating liquids

Our coating tanks are optimised for process, mixing and stirring processes for water and solvent-based products, using the smallest possible residual stirring volume. Dispersing and homogenisation are at the forefront for the reproducibility of coating and spraying liquid processes. Coating tanks can be optimised through our IRIS monitoring system. Our products are used and valued by manufacturers of coating and granulate systems as well as producers of pharmaceutical products.
Bild58

Articles in the range Coating tanks

Bild11
Cosmetics industry Pharmaceutical

120l ATEX stirring tank with control cabinet

Pharmaceutical process tank for coating liquids pursuant to PED 2014/68/EU module G, ATEX Directive 2014/34/EU and MD 2006/42/EU.
Top section as pressure dome cover with welded conical nozzle. Conical base design. The tank is characterised by its low residual stirring volume. This is approx. 1.0l.

The tank is equipped with a heating/cooling jacket and insulation cover.

Equipment also includes:
  • ATEX propeller for a viscosity of 250 mPas
  • Metaglas sight glass
  • LED sight glass lights
  • Rupture disc / safety valve
  • Product tubes
  • CIP cleaning nozzle
  • ATEX design
AREA OF APPLICATION:
Industry: Pharmaceutical
Product: Coating liquids, spraying liquids
SIZE:
10 l – 500 l
OPERATING DATA:
Tank product chamber:
p = -1 / +3 bar,
t = -10 / +150 °C
Double wall:
p = -1 / +3,5 bar,
t = -10 / +150 °C
MATERIAL:
Parts in contact with product 1.4404/ 1.4435/ 316L , with APZ 3.1 AD 2000, Ra <0.3µm
Request article
Configure article

Company

portfolio

links

Dear Sir or Madam,
Dear Mr Weinert,
27.04.2021


On April 30, 2021, we will open another site at Allergopharma GmbH & Co. KG in Reinbek to support COVID 19 vaccine production in the presence of Federal Minister Spahn and Minister President Günther. We would have been pleased to invite you to this opening.

Unfortunately, this was not possible due to the pandemic.
We would therefore like to take this opportunity to thank you for your extraordinary commitment to supplying equipment at short notice to support vaccine production. Allergopharma, as part of Dermapharm Holding SE, is now a further partner in the Europe-wide production network for the vaccine of BioNTech and Pfizer. This network now comprises more than a dozen important pharmaceutical manufacturers and suppliers. From now on, one of four production steps will take place in Reinbek: the vaccine formulation. This is where our mRNA active ingredient is combined with the lipids. A protective shell is created around the mRNA and the vaccine can reach its target in the body to induce the necessary immune response.


Your company has made a very important contribution to the global pandemic response with great know-how and under incredible time pressure. We would like to express our sincere thanks to you and your team! Without their commitment, the successful completion of the project would not have been possible.
We look forward to working with you in partnership in the future!

Dr. Hans-Georg Feldmeier – CEO Dermapharm SE
Dr. Sierk Poetting – CFO and COO BioNTech SE